Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...
55m
Stock futures are mixed Thursday morning as investors react to a barrage of earnings reports from major companies and important economic indicators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback